Market Research Logo

Dementia - Pipeline Review, H2 2015

Dementia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Dementia - Pipeline Review, H2 2015’, provides an overview of the Dementia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dementia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Dementia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Dementia Overview
Therapeutics Development
Pipeline Products for Dementia - Overview
Pipeline Products for Dementia - Comparative Analysis
Dementia - Therapeutics under Development by Companies
Dementia - Therapeutics under Investigation by Universities/Institutes
Dementia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Dementia - Products under Development by Companies
Dementia - Products under Investigation by Universities/Institutes
Dementia - Companies Involved in Therapeutics Development
Adamas Pharmaceuticals, Inc.
Addex Therapeutics Ltd
Alector LLC
AlzProtect SAS
Apceth GmbH & Co. KG
BioArctic Neuroscience AB
Biogen, Inc.
Biotie Therapies Corp.
Chase Pharmaceuticals Corporation
Chronos Therapeutics Limited
Daewoong Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
FORUM Pharmaceuticals Inc.
H. Lundbeck A/S
Hyundai Pharmaceutical Co., Ltd.
Ildong Pharmaceutical Co., Ltd.
IMMD Inc.
ImStar Therapeutics Inc.
Integrative Research Laboratories Sweden AB
Intellect Neurosciences, Inc.
Intra-Cellular Therapies, Inc.
MediPost Co., Ltd.
Neurimmune Holding AG
Neurodyn Inc.
Neuropore Therapies, Inc.
Oryzon Genomics S.A.
Otsuka Holdings Co., Ltd.
Pacific Northwest Biotechnology, LLC
Pivot Pharmaceuticals Inc
ProteoTech, Inc.
Sinil Pharmaceutical Co., Ltd
SK Chemicals Co., Ltd.
Stelic Institute & Co.
Sumitomo Dainippon Pharma Co., Ltd.
Sylentis S.A.
TauRx Therapeutics Ltd.
Tautatis Incorporated
Varinel, Inc.
WhanIn Pharmaceutical Co., Ltd.
Dementia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(memantine hydrochloride ER + donepezil hydrochloride) - Drug Profile
Antisense Oligonucleotides to Inhibit microRNA for Neurology - Drug Profile
Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile
APC-621 - Drug Profile
aripiprazole - Drug Profile
AVCRI-104P3 - Drug Profile
AZP-2006 - Drug Profile
BAN-0805 - Drug Profile
brexpiprazole - Drug Profile
CB-2233 - Drug Profile
CB-8411 - Drug Profile
choline alfoscerate SR - Drug Profile
CPC-201 - Drug Profile
CPC-252 - Drug Profile
D-217 - Drug Profile
dehydroevodiamine hydrochloride - Drug Profile
dipraglurant IR - Drug Profile
Drugs for Dementia - Drug Profile
Drugs to Agonize c-MET for Dementia - Drug Profile
Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile
DWJ-1365 - Drug Profile
E-2609 - Drug Profile
encenicline hydrochloride - Drug Profile
FRM-0334 - Drug Profile
GIBH-130 - Drug Profile
Gln-1062 - Drug Profile
GTC-6000 - Drug Profile
gugulipid - Drug Profile
HOB-075 - Drug Profile
IIPP-1 - Drug Profile
IMD-4482 - Drug Profile
IRL-752 - Drug Profile
ITI-007 - Drug Profile
KR-12 - Drug Profile
LUAF-20513 - Drug Profile
MM-201 - Drug Profile
Monoclonal Antibodies for Dementia and Alzheimer's Disease - Drug Profile
Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile
NAT - Drug Profile
Neurostem - Drug Profile
NI-205 - Drug Profile
NI-308 - Drug Profile
NNC-269100 - Drug Profile
OG-635 - Drug Profile
OV-201 - Drug Profile
P-003 - Drug Profile
PD-61W3 - Drug Profile
Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile
PST-900 - Drug Profile
RDC-5 - Drug Profile
SID-111 - Drug Profile
SIN-1502 - Drug Profile
Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile
Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile
Small Molecules for Ophthalmology and CNS Disorders - Drug Profile
Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile
Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease - Drug Profile
SYN-120 - Drug Profile
Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile
TAK-070 - Drug Profile
TauC-3 - Drug Profile
TPI-287 - Drug Profile
TRx-0237 - Drug Profile
TTT-3002 - Drug Profile
VAR-10100 - Drug Profile
WIB-1001C - Drug Profile
zonisamide - Drug Profile
Dementia - Recent Pipeline Updates
Dementia - Dormant Projects
Dementia - Discontinued Products
Dementia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Dementia, H2 2015
Number of Products under Development for Dementia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Dementia - Pipeline by Adamas Pharmaceuticals, Inc., H2 2015
Dementia - Pipeline by Addex Therapeutics Ltd, H2 2015
Dementia - Pipeline by Alector LLC, H2 2015
Dementia - Pipeline by AlzProtect SAS, H2 2015
Dementia - Pipeline by Apceth GmbH & Co. KG, H2 2015
Dementia - Pipeline by BioArctic Neuroscience AB, H2 2015
Dementia - Pipeline by Biogen, Inc., H2 2015
Dementia - Pipeline by Biotie Therapies Corp., H2 2015
Dementia - Pipeline by Chase Pharmaceuticals Corporation, H2 2015
Dementia - Pipeline by Chronos Therapeutics Limited, H2 2015
Dementia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
Dementia - Pipeline by Eisai Co., Ltd., H2 2015
Dementia - Pipeline by FORUM Pharmaceuticals Inc., H2 2015
Dementia - Pipeline by H. Lundbeck A/S, H2 2015
Dementia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2015
Dementia - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2015
Dementia - Pipeline by IMMD Inc., H2 2015
Dementia - Pipeline by ImStar Therapeutics Inc., H2 2015
Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2015
Dementia - Pipeline by Intellect Neurosciences, Inc., H2 2015
Dementia - Pipeline by Intra-Cellular Therapies, Inc., H2 2015
Dementia - Pipeline by MediPost Co., Ltd., H2 2015
Dementia - Pipeline by Neurimmune Holding AG, H2 2015
Dementia - Pipeline by Neurodyn Inc., H2 2015
Dementia - Pipeline by Neuropore Therapies, Inc., H2 2015
Dementia - Pipeline by Oryzon Genomics S.A., H2 2015
Dementia - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Dementia - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2015
Dementia - Pipeline by Pivot Pharmaceuticals Inc, H2 2015
Dementia - Pipeline by ProteoTech, Inc., H2 2015
Dementia - Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2015
Dementia - Pipeline by SK Chemicals Co., Ltd., H2 2015
Dementia - Pipeline by Stelic Institute & Co., H2 2015
Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Dementia - Pipeline by Sylentis S.A., H2 2015
Dementia - Pipeline by TauRx Therapeutics Ltd., H2 2015
Dementia - Pipeline by Tautatis Incorporated, H2 2015
Dementia - Pipeline by Varinel, Inc., H2 2015
Dementia - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Dementia Therapeutics - Recent Pipeline Updates, H2 2015
Dementia - Dormant Projects, H2 2015
Dementia - Dormant Projects (Contd..1), H2 2015
Dementia - Dormant Projects (Contd..2), H2 2015
Dementia - Dormant Projects (Contd..3), H2 2015
Dementia - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Dementia, H2 2015
Number of Products under Development for Dementia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report